According to VIC Research’s comprehensive market research and in-depth analysis, the Leukemia Molecular Diagnostics market is expected to reach USD 3,397.23 million in 2026 and is projected to grow to USD 6,853.82 million by 2033, registering a CAGR of 10.55% during the forecast period (2026–2033). Notably, the China Leukemia Molecular Diagnostics market has experienced significant growth in recent years. By 2026, China’s market size is projected to reach USD Million, accounting for approximately % of the global market share.
This report provides a comprehensive overview of the global Leukemia Molecular Diagnostics industry, with a particular focus on major countries and the Chinese market. It includes historical data from 2021 to 2025, uses 2026 as the base year, and presents forecasts for the period 2027 to 2033. The study systematically analyzes the sales performance, market share, pricing, sales volume, revenue, and gross profit of leading companies across key regions while tracking their strategic developments. In addition, it offers detailed market share analysis by manufacturer, product type, and application across different regions. The report is designed to help businesses, investors, and new market entrants better understand demand trends, growth opportunities, and competitive dynamics for informed strategic decision-making.
Geographically, the report covers North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa, providing an in-depth assessment of current market conditions and future growth prospects across these regions. By incorporating relevant industry policies and the latest technological developments, the report highlights the unique characteristics of each regional market. This enables organizations to gain deeper insights into regional competitive landscapes, optimize business strategies, and strengthen their global expansion plans.
The data presented in this report is compiled from a wide range of authoritative and reliable sources to ensure a strong analytical foundation. Macroeconomic information is sourced from national statistical agencies and international economic research institutions, while industry-specific data is collected from recognized trade associations. Company information is obtained through publicly available resources, industry interviews, and trusted third-party databases, while pricing data is gathered through comprehensive market monitoring systems. By integrating and cross-validating data from multiple sources, the report ensures high standards of accuracy, objectivity, and forward-looking analysis.
The report focuses on the following companies:
Ruiang Gene
Zhishan Bio
Zhijiang Bio
Jinpujia Medical
Merle Bio
Herui Gene
Aicon Bio
Annuouda
Beijing Wantai
Haixi Bio
Qiagen
Abbott
Kanglu Biotechnology
Guangzhou Anbiping
Based on different product types, the following categories are included:
PCR
FISH
DNA Sequencing
Gene Chip
By different sectors and application scenarios, the report primarily covers the following aspects:
Clinical Diagnosis
Drug Screening
Research
Major consumption regions include the following:
US
Europe
China
Japan
Korea
India
Southeast Asia
South America
This report is divided into five main sections comprising 10 chapters. The main content of each chapter is as follows:
Part One is the Foundational Section, primarily comprising Chapter 1, which introduces the market overview, fundamental concepts, product definition, key characteristics, product classifications, major application scenarios, and the industrial chain structure of the Leukemia Molecular Diagnostics market.
Part Two is the Global Section, primarily comprising Chapters 2–4, focusing on sales volume, market size, and growth forecasts across different product segments and application areas in the global Leukemia Molecular Diagnostics market.
Part Three is the Regional Section, primarily comprising Chapters 5–6, providing detailed analysis of sales volume, market size, and growth projections across the major regional markets for Leukemia Molecular Diagnostics.
Part Four is the Corporate Analysis, primarily covering Chapters 7–8, which examines the profiles of leading global Leukemia Molecular Diagnostics companies, including their product portfolios, technologies, applications, business strategies, sales performance, market share, and industry competitiveness.
Part Five is the Outlook Section, comprising Chapters 9–10, which evaluates the development environment, growth opportunities, market challenges, and potential risks facing the Leukemia Molecular Diagnostics industry, while presenting an outlook for future market development.
-
- Market Overview
1.1 Product Introduction, Application, Picture
1.2 Global Leukemia Molecular Diagnostics Market by Value
1.2.1 Global Leukemia Molecular Diagnostics Revenue by Type
1.2.2 Global Leukemia Molecular Diagnostics Market Share by Value (%)
1.3 Global Leukemia Molecular Diagnostics Market by Production
1.3.1 Global Leukemia Molecular Diagnostics Production by Type
1.3.2 Global Leukemia Molecular Diagnostics Market Share by Production (%) - Key Growth Drivers of the Leukemia Molecular Diagnostics Industry
2.1 Historical and Forecast Global Leukemia Molecular Diagnostics Demand
2.2 Largest Application Segment for Leukemia Molecular Diagnostics (2021–2032)
2.3 Major Downstream Companies in the China Market (2026) - Global and Regional Market Analysis
3.1 Regional Market Size by Production and Demand (2026)
3.2 Regional Market Share by Revenue (2026–2032)
3.3 Market Concentration Ratio (CR5 & CR10) of Leukemia Molecular Diagnostics
3.4 Mergers & Acquisitions and Expansion Strategies - US Leukemia Molecular Diagnostics Production and Demand (2021–2032)
4.1 Current and Forecast Production by Type
4.2 Current and Forecast Demand by Type
4.3 Current and Forecast Demand by Application
4.4 Current and Forecast Revenue by Type (2021–2032)
4.5 Current and Forecast Revenue by Application (2021–2032) - Europe Leukemia Molecular Diagnostics Production and Demand (2021–2032)
5.1 Current and Forecast Production by Type
5.2 Current and Forecast Demand by Type
5.3 Current and Forecast Demand by Application
5.4 Current and Forecast Revenue by Type (2021–2032)
5.5 Current and Forecast Revenue by Application (2021–2032) - China Leukemia Molecular Diagnostics Production and Demand (2021–2032)
6.1 Current and Forecast Production by Type
6.2 Current and Forecast Demand by Type
6.3 Current and Forecast Demand by Application
6.4 Current and Forecast Revenue by Type (2021–2032)
6.5 Current and Forecast Revenue by Application (2021–2032) - Japan Leukemia Molecular Diagnostics Production and Demand (2021–2032)
7.1 Current and Forecast Production by Type
7.2 Current and Forecast Demand by Type
7.3 Current and Forecast Demand by Application
7.4 Current and Forecast Revenue by Type (2021–2032)
7.5 Current and Forecast Revenue by Application (2021–2032) - India Leukemia Molecular Diagnostics Production and Demand (2021–2032)
8.1 Current and Forecast Production by Type
8.2 Current and Forecast Demand by Type
8.3 Current and Forecast Demand by Application
8.4 Current and Forecast Revenue by Type (2021–2032)
8.5 Current and Forecast Revenue by Application (2021–2032) - Korea Leukemia Molecular Diagnostics Production and Demand (2021–2032)
9.1 Current and Forecast Production by Type
9.2 Current and Forecast Demand by Type
9.3 Current and Forecast Demand by Application
9.4 Current and Forecast Revenue by Type (2021–2032)
9.5 Current and Forecast Revenue by Application (2021–2032) - Southeast Asia Leukemia Molecular Diagnostics Production and Demand (2021–2032)
10.1 Current and Forecast Production by Type
10.2 Current and Forecast Demand by Type
10.3 Current and Forecast Demand by Application
10.4 Current and Forecast Revenue by Type (2021–2032)
10.5 Current and Forecast Revenue by Application (2021–2032) - South America Leukemia Molecular Diagnostics Production and Demand (2021–2032)
11.1 Current and Forecast Production by Type
11.2 Current and Forecast Demand by Type
11.3 Current and Forecast Demand by Application
11.4 Current and Forecast Revenue by Type (2021–2032)
11.5 Current and Forecast Revenue by Application (2021–2032) - Global Leukemia Molecular Diagnostics Average Price Trend
13.1 Market Price by Product Type in the US (2021–2026)
13.2 Market Price by Product Type in Europe (2021–2026)
13.3 Market Price by Product Type in China (2021–2026)
13.4 Market Price by Product Type in Japan (2021–2026)
13.5 Market Price by Product Type in India (2021–2026)
13.6 Market Price by Product Type in Korea (2021–2026)
13.7 Market Price by Product Type in Southeast Asia (2021–2026) - Industrial Chain Analysis
14.1 Leukemia Molecular Diagnostics Industry Chain Analysis
14.2 Downstream Industry Analysis
14.3 Technology Trends in Leukemia Molecular Diagnostics - Competitive Landscape
15.1 Company One
15.1.1 Ruiang Gene Profile
15.1.2 Ruiang Gene Product Introduction
15.1.3 Ruiang Gene Leukemia Molecular Diagnostics Sales and Revenue
15.1.4 Strategic Initiatives
15.2 Zhishan Bio
15.2.1 Zhishan Bio Profile
15.2.2 Zhishan Bio Product Introduction
15.2.3 Zhishan Bio Leukemia Molecular Diagnostics Sales and Revenue
15.2.4 Strategic Initiatives15.3 Zhijiang Bio
15.3.1 Zhijiang Bio Profile
15.3.2 Zhijiang Bio Product Introduction
15.3.3 Zhijiang Bio Leukemia Molecular Diagnostics Sales and Revenue
15.3.4 Strategic Initiatives15.4 Jinpujia Medical
15.4.1 Jinpujia Medical Profile
15.4.2 Jinpujia Medical Product Introduction
15.4.3 Jinpujia Medical Leukemia Molecular Diagnostics Sales and Revenue
15.4.4 Strategic Initiatives15.5 Merle Bio
15.5.1 Merle Bio Profile
15.5.2 Merle Bio Product Introduction
15.5.3 Merle Bio Leukemia Molecular Diagnostics Sales and Revenue
15.5.4 Strategic Initiatives15.6 Herui Gene
15.6.1 Herui Gene Profile
15.6.2 Herui Gene Product Introduction
15.6.3 Herui Gene Leukemia Molecular Diagnostics Sales and Revenue
15.6.4 Strategic Initiatives15.7 Aicon Bio
15.7.1 Aicon Bio Profile
15.7.2 Aicon Bio Product Introduction
15.7.3 Aicon Bio Leukemia Molecular Diagnostics Sales and Revenue
15.7.4 Strategic Initiatives15.8 Annuouda
15.8.1 Annuouda Profile
15.8.2 Annuouda Product Introduction
15.8.3 Annuouda Leukemia Molecular Diagnostics Sales and Revenue
15.8.4 Strategic Initiatives15.9 Beijing Wantai
15.10 Haixi Bio
15.11 Qiagen
15.12 Abbott
15.13 Kanglu Biotechnology
15.14 Guangzhou Anbiping- Conclusion
- Research Method
- Market Overview
-
Figure 1. Total Demand by Application of Leukemia Molecular Diagnostics Industry (Volume)
Figure 2. Leukemia Molecular Diagnostics Production and Demand by Region (2026)
Figure 3. Regional Market Share by Revenue (2026–2032)
Figure 4. Market Share of the Top 10 and Top 5 Players by Revenue (2026)
Figure 5. US Leukemia Molecular Diagnostics Production and Demand (2021–2032)
Figure 6. Production Breakdown by Type (%)
Figure 7. Demand Breakdown by Type (%)
Figure 8. Demand Breakdown by Application (%)
Figure 9. Revenue Breakdown by Type (%)
Figure 10. Revenue Breakdown by Application (%)
Figure 11. Europe Leukemia Molecular Diagnostics Production and Demand (2021–2032)
Figure 12. Production Breakdown by Type (%)
Figure 13. Demand Breakdown by Type (%)
Figure 14. Demand Breakdown by Application (%)
Figure 15. Revenue Breakdown by Type (%)
Figure 16. Revenue Breakdown by Application (%)
Figure 17. China Leukemia Molecular Diagnostics Production and Demand (2021–2032)
Figure 18. Production Breakdown by Type (%)
Figure 19. Demand Breakdown by Type (%)
Figure 20. Demand Breakdown by Application (%)
Figure 21. Revenue Breakdown by Type (%)
Figure 22. Revenue Breakdown by Application (%)
Figure 23. Japan Leukemia Molecular Diagnostics Production and Demand (2021–2032)
Figure 24. Production Breakdown by Type (%)
Figure 25. Demand Breakdown by Type (%)
Figure 26. Demand Breakdown by Application (%)
Figure 27. Revenue Breakdown by Type (%)
Figure 28. Revenue Breakdown by Application (%)
Figure 29. India Leukemia Molecular Diagnostics Production and Demand (2021–2032)
Figure 30. Production Breakdown by Type (%)
Figure 31. Demand Breakdown by Type (%)
Figure 32. Demand Breakdown by Application (%)
Figure 33. Revenue Breakdown by Type (%)
Figure 34. Revenue Breakdown by Application (%)
Figure 35. Korea Leukemia Molecular Diagnostics Production and Demand (2021–2032)
Figure 36. Production Breakdown by Type (%)
Figure 37. Demand Breakdown by Type (%)
Figure 38. Demand Breakdown by Application (%)
Figure 39. Revenue Breakdown by Type (%)
Figure 40. Revenue Breakdown by Application (%)
Figure 41. Southeast Asia Leukemia Molecular Diagnostics Production and Demand (2021–2032)
Figure 42. Production Breakdown by Type (%)
Figure 43. Demand Breakdown by Type (%)
Figure 44. Demand Breakdown by Application (%)
Figure 45. Revenue Breakdown by Type (%)
Figure 46. Revenue Breakdown by Application (%)
Figure 47. South America Leukemia Molecular Diagnostics Production and Demand (2021–2032)
Figure 48. Production Breakdown by Type (%)
Figure 49. Demand Breakdown by Type (%)
Figure 50. Demand Breakdown by Application (%)
Figure 51. Revenue Breakdown by Type (%)
Figure 52. Revenue Breakdown by Application (%)
Figure 53. Industrial Chain AnalysisTable 1. Top Manufacturers and Market Segmentation
Table 2. Product Introduction, Application, and Image
Table 3. Leukemia Molecular Diagnostics Revenue by Type (Million USD), 2021–2032
Table 4. Leukemia Molecular Diagnostics Production by Type, 2021–2032
Table 5. Leukemia Molecular Diagnostics Demand by Application, 2021–2032
Table 6. Leukemia Molecular Diagnostics Demand by Application (Million USD), 2021–2032
Table 7. Major Downstream Companies in China
Table 8. Regional Market Share by Production and Demand (2026)
Table 9. Regional Market Share by Revenue (2026–2032)
Table 10. Ranking of Global Leading Leukemia Molecular Diagnostics Companies by Revenue and Market Concentration Ratio (2026)
Table 11. Mergers, Acquisitions, and Expansion Plans
Table 12. US Leukemia Molecular Diagnostics Production, Revenue (Million USD), and Demand (2021–2032)
Table 13. Current and Forecast Production Breakdown by Type (2021–2032)
Table 14. Current and Forecast Demand Breakdown by Type (2021–2032)
Table 15. Current and Forecast Demand Breakdown by Application (2021–2032)
Table 16. Current and Forecast Revenue Breakdown by Type
Table 17. Current and Forecast Revenue Breakdown by Application
Table 18. Europe Leukemia Molecular Diagnostics Production, Revenue (Million USD), and Demand (2021–2032)
Table 19. Current and Forecast Production Breakdown by Type (2021–2032)
Table 20. Current and Forecast Demand Breakdown by Type (2021–2032)
Table 21. Current and Forecast Demand Breakdown by Application (2021–2032)
Table 22. Current and Forecast Revenue Breakdown by Type
Table 23. Current and Forecast Revenue Breakdown by Application
Table 24. China Leukemia Molecular Diagnostics Production, Revenue (Million USD), and Demand (2021–2032)
Table 25. Current and Forecast Production Breakdown by Type (2021–2032)
Table 26. Current and Forecast Demand Breakdown by Type (2021–2032)
Table 27. Current and Forecast Demand Breakdown by Application (2021–2032)
Table 28. Current and Forecast Revenue Breakdown by Type
Table 29. Current and Forecast Revenue Breakdown by Application
Table 30. Japan Leukemia Molecular Diagnostics Production, Revenue (Million USD), and Demand (2021–2032)
Table 31. Current and Forecast Production Breakdown by Type (2021–2032)
Table 32. Current and Forecast Demand Breakdown by Type (2021–2032)
Table 33. Current and Forecast Demand Breakdown by Application (2021–2032)
Table 34. Current and Forecast Revenue Breakdown by Type
Table 35. Current and Forecast Revenue Breakdown by Application
Table 36. India Leukemia Molecular Diagnostics Production, Revenue (Million USD), and Demand (2021–2032)
Table 37. Current and Forecast Production Breakdown by Type (2021–2032)
Table 38. Current and Forecast Demand Breakdown by Type (2021–2032)
Table 39. Current and Forecast Demand Breakdown by Application (2021–2032)
Table 40. Current and Forecast Revenue Breakdown by Type
Table 41. Current and Forecast Revenue Breakdown by Application
Table 42. Korea Leukemia Molecular Diagnostics Production, Revenue (Million USD), and Demand (2021–2032)
Table 43. Current and Forecast Production Breakdown by Type (2021–2032)
Table 44. Current and Forecast Demand Breakdown by Type (2021–2032)
Table 45. Current and Forecast Demand Breakdown by Application (2021–2032)
Table 46. Current and Forecast Revenue Breakdown by Type
Table 47. Current and Forecast Revenue Breakdown by Application
Table 48. Southeast Asia Leukemia Molecular Diagnostics Production, Revenue (Million USD), and Demand (2021–2032)
Table 49. Current and Forecast Production Breakdown by Type (2021–2032)
Table 50. Current and Forecast Demand Breakdown by Type (2021–2032)
Table 51. Current and Forecast Demand Breakdown by Application (2021–2032)
Table 52. Current and Forecast Revenue Breakdown by Type
Table 53. Current and Forecast Revenue Breakdown by Application
Table 54. South America Leukemia Molecular Diagnostics Production, Revenue (Million USD), and Demand (2021–2032)
Table 55. Current and Forecast Production Breakdown by Type (2021–2032)
Table 56. Current and Forecast Demand Breakdown by Type (2021–2032)
Table 57. Current and Forecast Demand Breakdown by Application (2021–2032)
Table 58. Current and Forecast Revenue Breakdown by Type
Table 59. Current and Forecast Revenue Breakdown by Application
Table 60. Market Price by Type in the US (2021–2026)
Table 61. Market Price by Type in Europe (2021–2026)
Table 62. Market Price by Type in China (2021–2026)
Table 63. Market Price by Type in Japan (2021–2026)
Table 64. Market Price by Type in India (2021–2026)
Table 65. Market Price by Type in Korea (2021–2026)
Table 66. Market Price by Type in Southeast Asia (2021–2026)
Table 67. Key Downstream Customers by Application
Table 68. Ruiang Gene Profile
Table 69. Ruiang Gene Product Introduction
Table 70. Ruiang Gene Leukemia Molecular Diagnostics Sales (Units) and Revenue (Million USD) (2021–2026)
Table 71. Zhishan Bio Profile
Table 72. Zhishan Bio Product Introduction
Table 73. Zhishan Bio Leukemia Molecular Diagnostics Sales (Units) and Revenue (Million USD) (2021–2026)
Table 74. Zhijiang Bio Profile
Table 75. Zhijiang Bio Product Introduction
Table 76. Zhijiang Bio Leukemia Molecular Diagnostics Sales (Units) and Revenue (Million USD) (2021–2026)
Table 77. Jinpujia Medical Profile
Table 78. Jinpujia Medical Product Introduction
Table 79. Jinpujia Medical Leukemia Molecular Diagnostics Sales (Units), Revenue (Million USD), and Price (2021–2026)
Table 83. Herui Gene Profile
Table 84. Herui Gene Product Introduction
Table 85. Herui Gene Leukemia Molecular Diagnostics Sales (Units) and Revenue (Million USD) (2021–2026)
Table 86. Aicon Bio Profile
Table 87. Aicon Bio Product Introduction
Table 88. Aicon Bio Leukemia Molecular Diagnostics Sales (Units) and Revenue (Million USD) (2021–2026)
Table 89. Annuouda Profile
Table 90. Annuouda Product Introduction
Table 91. Annuouda Leukemia Molecular Diagnostics Sales (Units) and Revenue (Million USD) (2021–2026)
-
The research methodology employed by VICResearch follows a series of rigorous procedures to ensure the quality and accuracy of the data presented in its reports. Our analysts are employed full-time and undergo more than six months of professional training to meet VICResearch’s quality standards. The research methodology is divided into the following five stages:
Stage 1: Secondary Research
The research team begins by reviewing magazines, industry trade associations, and government organizations operating within the relevant research field. Information provided through our in-house documentation service supports further research activities. Leveraging both industry expertise and extensive experience, our analysts efficiently extract accurate and reliable information from existing sources.
Stage 2: Primary Research: Interviews with Trade Sources
Following the secondary research stage, the research team conducts a large number of face-to-face and telephone interviews with representative companies operating within the industry. Analysts seek opportunities to engage with both leading market participants and smaller companies. Interviews include upstream suppliers, manufacturers, distributors, importers, installers, wholesalers, and end users. The information collected through these interviews is carefully verified and cross-checked against the findings from the secondary research.
Stage 3: Analysis of the Gathered Data
The analysis team reviews, validates, and consolidates the data collected during the first two stages. Where necessary, an additional round of interviews is conducted to further verify and strengthen the accuracy of the findings.
Stage 4: Quantitative Data
VICResearch provides quantitative data covering market estimates, production capacity, manufacturer output, market forecasts, and investment feasibility. These figures are based on the validated estimates developed during Stage 3.
In addition, the research team delivers comprehensive market assessments and analytical insights alongside the quantitative data contained in the reports. As a result, the research findings are unique to VICResearch.
Stage 5: Quality Control
Before publication, every report undergoes a rigorous review and editing process conducted by our experienced management team to ensure the reliability and consistency of the published data. Each analyst also receives continuous guidance and ongoing training as part of VICResearch’s internal quality assurance process.